Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)

Inclusion Criteria19

• Retrospective cohort
• \>18 years old;
• Patients previously included in the ADAPT-CTC trial
• Prospective cohort
• \>18 years old
• Histologic confirmation (primary or metastatic tumor) of Acinar Adenocarcinoma of Prostate
• Hormone-sensitive OMPC defined as ≤3 metachronous metastases (bone and/or lymph node) detected within the past 6 months with Choline/PSMA PET-CT following prostate specific antigen (PSA) rising after primary treatment (surgery and/or radiotherapy) with curative intent as defined by European Association of Urology criteria (EAU).
• Controlled primary tumor
• Prior salvage treatment to the primary prostate cancer is allowed.
• PSA ≤ 50 ng/mL
• Testosterone ≥ 0.5 ng/mL
• ADT associated to the primary treatment concluded more than 6 months prior to the enrollment.
• Patients eligible for a course of SBRT on bone and/or lymph node metastatic sites
• Patients must have a life expectancy ≥ 12 months and an ECOG performance status ≤ 2
• Patients must have normal organ and marrow function defined as:
• Leukocytes ≥2000/µL
• Absolute Neutrophil Count ≥1000/µL
• Platelets ≥50000/µL
• Patients amenable to understand and sign written informed consent documents